News
Insulet Delivers 26% Revenue Growth and Raises 2017 Guidance; Stock Pumps Up 7%
Insulet (NASDAQ: PODD) reported second-quarter 2017 earnings after the market closed on Thursday. The drug-delivery company, which is a leader in tubeless insulin pump technology with its Omnipod
Down 9.8%: Is Masimo Corporation Stock a Contrarian Buy?
Masimo Corporation (NASDAQ: MASI), a mid-cap medical technology company, reported stronger-than-expected second-quarter results after the bell Wednesday, but investors still decided to hit the exits
Here's What's Pressuring Glaukos Corp Stock Today
Shares of Glaukos Corp (NYSE: GKOS), a medical technology company focused on glaucoma treatment, were down about 9.8% as of 11:46 a.m. on Thursday in response to a second-quarter earnings report
Genomic Health, Inc.: Still Waiting for Reimbursement
Genomic Health's (NASDAQ: GHDX) revenue continues to grow slowly because of a delay in Medicare reimbursement for its prostate cancer test, but the genomic test maker was still able to reduce its net
Globus Medical Enjoys Another Solid Quarter Thanks to International Sales Growth
So far, 2017 is shaping up to be the best year for Globus Medical (NYSE: GMED) shareholders in quite a while. The musculoskeletal implant manufacturer posted great numbers for the first quarter
3 Exciting Biotechs Under $30: Novocure Is Revolutionizing Brain Cancer Treatment
Novocure (NASDAQ: NVCR) is the company behind TTFields, a revolutionary new and nontoxic treatment for glioblastoma that uses low-intensity, alternating electrical fields to impede cancerous cell
Here's Why Spark Therapeutics Inc. Is Soaring Today
After reporting second-quarter results that contained upbeat clinical news, Spark Therapeutics (NASDAQ: ONCE), a clinical-stage company focused on gene therapy, rose 18% as of 12:30 p.m. EDT on
Here's Why Amarin Corporation plc Is on the Rise Today
Shares of Amarin Corporation plc (NASDAQ: AMRN), a cardiovascular health-focused biotech, popped 12.9% higher this morning after reporting second-quarter earnings. Investors cheered the
It's Time for Investors to Get Over the Biggest Misconception About Valeant Pharmaceuticals
Nearly two years ago to the day, Valeant Pharmaceuticals (NYSE: VRX) would hit almost $264 a share in intraday trading and support a roughly $90 billion market valuation. The embattled drugmaker has
Evotec: Rekordübernahme!
Wieder gute News vom Wirkstoffhersteller Evotec. Wie das Unternehmen mitteilt, soll der US-Konkurrent Aptuit für rund 300 Mio. USD übernommen werden. Das ist der größte Zukauf in der....
Better Buy: Cara Therapeutics Inc. vs. GW Pharmaceuticals plc
Cara Therapeutics Inc. (NASDAQ: CARA), and GW Pharmaceuticals plc (NASDAQ: GWPH) often get lumped in with a stack of risky marijuana stocks, because both are developing drugs derived from the
President Trump's Breaking of This 148-Year Streak Won't Slow This Trend One Bit
When Donald Trump entered the Oval Office, we knew things would be a bit different. After all, he's the first president ever to not have any military or political experience, and he's just the second
Why Mednax Tumbled 12% Today Despite Higher Sales
Despite reporting 9.2% year-over-year sales growth, a sharp decline in profitability sent shares in Mednax (NYSE: MD) lower Friday. Shares were down 11.9% at noon EDT. Mednax is a large provider of
Alkermes Continues to Execute
Alkermes (NASDAQ: ALKS), a biopharmaceutical company focused on diseases of the central nervous system, released its second-quarter earnings results on Thursday, July 27. The report showed that
Executive Changes Hit NuVasive Hard
Advances in medical science have had a dramatic impact on the quality of care that patients receive. In the area of spinal surgery, NuVasive (NASDAQ: NUVA) has made a lot of headway with its minimally
Why Amedisys Is Crashing 14.3% Today
After the Centers for Medicare and Medicaid Services (CMS) said it may reduce reimbursement for home healthcare by 0.4% in 2018, shares in Amedisys Inc. (NASDAQ: AMED) are losing 14.3% of their value
The 3 Hottest Marijuana Stocks Right Now
Though it probably goes without saying, it should be noted that marijuana stocks have been on fire over the trailing year. All but one of the 13 marijuana stocks with market caps above $200 million
It Took Just 10 Days for Nevada's Recreational Marijuana Industry to Fall Into a State of Emergency
When discussing the fastest-growing industries on the planet, few, or none, may top the legal marijuana industry. According to cannabis research group ArcView, North American legal pot sales are
2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't
Exelixis (NASDAQ: EXEL) is without question one of the hottest biotech stocks on the market. We're talking about a stock that has more than tripled in value in just the last 12 months and has soared
Better Buy: Valeant Pharmaceuticals International, Inc. vs. Gilead Sciences
When it comes to the high-flying healthcare sector, there aren't many bargains to be had. President Trump's recent change of heart regarding the possibility of hard caps on high-priced prescription
Valeant Just Showed Why Its Share Price Has Deservedly Fallen by 93% Since August 2015
Most drug companies have been relatively unstoppable over the past couple of years, partly because of the optimism surrounding a stock market that keeps hitting new all-time highs, and partly due to
AveXis Inc.: Buy at the High?
In the time it takes most newborns to sprout their first teeth, AveXis Inc. (NASDAQ: AVXS) looks ready to sink its teeth into the biotech industry. Since its market debut in early 2016, stellar
These 2 Companies Have No Competition
Warren Buffett has long championed the idea of investing in companies with durable competitive advantages. He believes that a business with true "moat" can more easily defend its market share from
Never Will I Ever Buy Preclinical Biotech Stocks. No Way!
It's "Never Will I Ever" week on Industry Focus, and we're explaining what we'll never invest in and why.It's incredibly difficult to develop new, game-changing medicine. How difficult? Over 90% of
Can Bellicum Pharmaceuticals Stock Bounce Back?
How you view a stock depends heavily on your point of reference. Bellicum Pharmaceuticals (NASDAQ: BLCM), for example, saw its share price fall nearly 14% in one day in late June. That's certainly not